{"id":2811,"date":"2022-07-09T12:00:53","date_gmt":"2022-07-09T03:00:53","guid":{"rendered":"https:\/\/www.pharm.kyoto-u.ac.jp\/byotai\/?page_id=2811"},"modified":"2025-04-15T14:48:31","modified_gmt":"2025-04-15T05:48:31","slug":"%e3%81%8c%e3%82%93%e3%81%ae%e7%97%85%e6%85%8b%e5%88%86%e6%9e%90%e3%81%8b%e3%82%89%e6%b2%bb%e7%99%82%e3%81%ab%e5%90%91%e3%81%91%e3%81%a6%e2%91%a1","status":"publish","type":"page","link":"https:\/\/www.pharm.kyoto-u.ac.jp\/byotai\/%e3%81%8c%e3%82%93%e3%81%ae%e7%97%85%e6%85%8b%e5%88%86%e6%9e%90%e3%81%8b%e3%82%89%e6%b2%bb%e7%99%82%e3%81%ab%e5%90%91%e3%81%91%e3%81%a6%e2%91%a1\/","title":{"rendered":"\u304c\u3093\u306e\u75c5\u614b\u5206\u6790\u304b\u3089\u6cbb\u7642\u306b\u5411\u3051\u3066\u2461"},"content":{"rendered":"<h2>\u653e\u5c04\u6027\u30d7\u30ed\u30fc\u30d6\u306e\u4f53\u5185\u52d5\u614b\u306e\u5316\u5b66\u5236\u5fa1\u306b\u3088\u308b\u9ad8\u52b9\u7387\u30e9\u30b8\u30aa\u30bb\u30e9\u30ce\u30b9\u30c6\u30a3\u30af\u30b9\u7528\u30d7\u30e9\u30c3\u30c8\u30db\u30fc\u30e0\u306e\u69cb\u7bc9<\/h2>\n<p>RI\u3092\u57fa\u76e4\u3068\u3057\u3066\u8a3a\u65ad(Diagnostics)\u3068\u6cbb\u7642(Therapeutics)\u3092\u7cfb\u7d71\u7684\u306b\u7d71\u5408\u3059\u308b\u30e9\u30b8\u30aa\u30bb\u30e9\u30ce\u30b9\u30c6\u30a3\u30af\u30b9(Radiotheranostics)\u306f\u304c\u3093\u9818\u57df\u3092\u4e2d\u5fc3\u306b\u6ce8\u76ee\u3092\u96c6\u3081\u3066\u3044\u308b\u3002\u3057\u304b\u3057\u30e9\u30b8\u30aa\u30bb\u30e9\u30ce\u30b9\u30c6\u30a3\u30af\u30b9\u85ac\u5264\u306e\u591a\u304f\u306f\u814e\u81d3\u306a\u3069\u306e\u6b63\u5e38\u7d44\u7e54\u3078\u306e\u975e\u7279\u7570\u7684\u96c6\u7a4d\u304c\u9ad8\u304f\u3001PET\/SPECT\u306b\u304a\u3051\u308b\u8a3a\u65ad\u7cbe\u5ea6\u306e\u4f4e\u4e0b\u3084RI\u5185\u7528\u7642\u6cd5\u306b\u304a\u3051\u308b\u9ad8\u3044\u814e\u6bd2\u6027\u304c\u61f8\u5ff5\u3055\u308c\u308b\u3002\u305d\u306e\u305f\u3081\u3001\u814e\u81d3\u3092\u306f\u3058\u3081\u3068\u3059\u308b\u6b63\u5e38\u7d44\u7e54\u3078\u306e\u96c6\u7a4d\u3092\u6291\u3048\u3001\u9ad8\u52b9\u7387\u306b\u6a19\u7684\u7d44\u7e54\u306b\u96c6\u7a4d\u3059\u308b\u30e9\u30b8\u30aa\u30bb\u30e9\u30ce\u30b9\u30c6\u30a3\u30af\u30b9\u85ac\u5264\u306e\u958b\u767a\u7814\u7a76\u3092\u884c\u3063\u3066\u3044\u308b\u3002<\/p>\n<p>\u30a2\u30eb\u30d6\u30df\u30f3\u30d0\u30a4\u30f3\u30c0\u30fc(ALB)\u306f\u8840\u6f3f\u4e2d\u306e\u30a2\u30eb\u30d6\u30df\u30f3\u3068\u53ef\u9006\u7684\u306b\u7d50\u5408\u3059\u308b\u5206\u5b50\u3067\u3042\u308a\u3001ALB\u3092\u5206\u5b50\u5185\u306b\u6709\u3059\u308b\u85ac\u5264\u306f\u814e\u81d3\u3067\u7cf8\u7403\u4f53\u308d\u904e\u3092\u53d7\u3051\u305a\u3001\u814e\u96c6\u7a4d\u304c\u4f4e\u6e1b\u3057\u3001\u8840\u6db2\u4e2d\u534a\u6e1b\u671f\u304c\u5ef6\u9577\u3059\u308b\u3053\u3068\u306b\u3088\u308a\u3001\u816b\u760d\u96c6\u7a4d\u304c\u5411\u4e0a\u3059\u308b\u3068\u8003\u3048\u3089\u308c\u308b\u3002\u305d\u3053\u3067\u6211\u3005\u306f\u3001\u6a19\u7684\u6307\u5411\u6027\u30ea\u30ac\u30f3\u30c9\u306bALB\u3092\u5c0e\u5165\u3059\u308b\u3053\u3068\u306b\u3088\u308a\uff0c\u30d7\u30ed\u30fc\u30d6\u306e\u4f53\u5185\u52d5\u614b\u3092\u5236\u5fa1\u3057\uff0c\u816b\u760d\/\u814e\u81d3\u6bd4\u306e\u6539\u5584\u3092\u56f3\u3063\u3066\u3044\u308b\u3002<\/p>\n<p><a href=\"https:\/\/www.pharm.kyoto-u.ac.jp\/byotai\/files\/2022\/07\/\u56f31.jpg\" class=\"liimagelink\"><img loading=\"lazy\" decoding=\"async\" class=\"aligncenter size-full wp-image-2812\" src=\"https:\/\/www.pharm.kyoto-u.ac.jp\/byotai\/files\/2022\/07\/\u56f31.jpg\" alt=\"\" width=\"841\" height=\"595\" srcset=\"https:\/\/www.pharm.kyoto-u.ac.jp\/byotai\/files\/2022\/07\/\u56f31.jpg 841w, https:\/\/www.pharm.kyoto-u.ac.jp\/byotai\/files\/2022\/07\/\u56f31-300x212.jpg 300w, https:\/\/www.pharm.kyoto-u.ac.jp\/byotai\/files\/2022\/07\/\u56f31-768x543.jpg 768w\" sizes=\"auto, (max-width: 841px) 100vw, 841px\" \/><\/a><\/p>\n<p>\u3053\u308c\u307e\u3067\u306b\uff0c\u6a19\u7684\u3068\u3057\u3066\u70ad\u9178\u8131\u6c34\u9175\u7d20IX (CAIX)\u3001\u524d\u7acb\u817a\u7279\u7570\u7684\u819c\u6297\u539f(PSMA)\u3001\u30b0\u30eb\u30ab\u30b4\u30f3\u69d8\u30da\u30d7\u30c1\u30c9-1(GLP-1)\u53d7\u5bb9\u4f53\u3092\u9078\u629e\u3057\uff0c\u305d\u308c\u306b\u5bfe\u3059\u308b\u8a8d\u8b58\u90e8\u4f4d\uff0c\u91d1\u5c5e\u914d\u4f4d\u5b50\uff0cALB\u3092\u5c0e\u5165\u3057\u305f\u76f4\u9396\u578b\u5206\u5b50\u3092\u8a2d\u8a08\u30fb\u5408\u6210\u3057\uff0c\u305d\u306e\u30e9\u30b8\u30aa\u30bb\u30e9\u30ce\u30b9\u30c6\u30a3\u30af\u30b9\u85ac\u5264\u3068\u3057\u3066\u306e\u6709\u7528\u6027\u306b\u3064\u3044\u3066\u8a55\u4fa1\u3092\u884c\u306a\u3063\u3066\u304d\u305f\uff0e<\/p>\n<p><a href=\"https:\/\/www.pharm.kyoto-u.ac.jp\/byotai\/files\/2023\/04\/\u56f32-2.jpg\" class=\"liimagelink\"><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-full wp-image-2914\" src=\"https:\/\/www.pharm.kyoto-u.ac.jp\/byotai\/files\/2023\/04\/\u56f32-2.jpg\" alt=\"\" width=\"841\" height=\"595\" srcset=\"https:\/\/www.pharm.kyoto-u.ac.jp\/byotai\/files\/2023\/04\/\u56f32-2.jpg 841w, https:\/\/www.pharm.kyoto-u.ac.jp\/byotai\/files\/2023\/04\/\u56f32-2-300x212.jpg 300w, https:\/\/www.pharm.kyoto-u.ac.jp\/byotai\/files\/2023\/04\/\u56f32-2-768x543.jpg 768w\" sizes=\"auto, (max-width: 841px) 100vw, 841px\" \/><\/a><\/p>\n<p>&nbsp;<\/p>\n<h3>\u4e3b\u8981\u8ad6\u6587<\/h3>\n<ul>\n<li><span class=\"Apple-style-span\">Effect of Linker Entities on Pharmacokinetics of <sup>111<\/sup>In-Labeled Prostate-Specific Membrane Antigen-Targeting Ligands with an Albumin Binder<br \/>\n<span lang=\"EN-US\"><em>ACS Pharmacol. Transl Sci.<\/em> 7(8) 2401-2413 (2024)<\/span><\/span><\/li>\n<li><span class=\"Apple-style-span\">Development of Novel <sup>111<\/sup>In\/<sup>225<\/sup>Ac-Labeled Agent Targeting PSMA for Highly Efficient Cancer Radiotheranostics<br \/>\n<span lang=\"EN-US\"><em>J. Med. Chem.<\/em>\u00a066(12) 8043-8053 (2023)<\/span><\/span><\/li>\n<li><span class=\"Apple-style-span\">Application of the Chelator-based Clickable Radiotheranostic Platform to Moderate-molecular-weight Ligands<br \/>\n<em>ACS Med Chem Lett<\/em>\u00a013(10) 1642-1647 (2022)<\/span><\/li>\n<li><span class=\"Apple-style-span\">Structure-activity relationships and pharmacokinetics of <sup>111<\/sup>In-labeled glucagon-like peptide-1 receptor-targeting exendin-4 derivatives conjugated with albumin binder moieties<br \/>\n<em>Mol Pharm<\/em>\u00a019(8) 2832-2839 (2022)<\/span><\/li>\n<li><span class=\"Apple-style-span\">Synthesis and evaluation of novel <sup>111<\/sup>In-labeled picolinic acid-based radioligands containing an albumin binder for development of radiotheranostic platform<br \/>\n<em>Mol Pharm<\/em> 19(8) 2725-2736 (2022)<\/span><\/li>\n<li><span class=\"Apple-style-span\">Development of an <sup>111<\/sup>In-Labeled Glucagon-Like Peptide-1 Receptor-Targeting Exendin-4 Derivative that Exhibits Reduced Renal Uptake<br \/>\n<em>Mol Pharm<\/em>\u00a019(3) 1019-1027 (2022)<\/span><\/li>\n<li><span class=\"Apple-style-span\">Development of a novel radiotheranostic platform with a DOTA-based trifunctional chelating agent prostate-specific membrane antigen<br \/>\n<em>Chem Commun<\/em>\u00a057 6432-6435 (2021)<\/span><\/li>\n<li><span class=\"Apple-style-span\">Radiotheranostics using a novel <sup>225<\/sup>Ac-labeled radioligand with improved pharmacokinetics targeting prostate-specific membrane antigen<br \/>\n<em>J Med Chem<\/em>\u00a064(18) 13429-13438 (2021)<\/span><\/li>\n<li><span class=\"Apple-style-span\">Modulation of pharmacokinetics of radioligand targeting carbonic anhydrase-IX utilizing albumin-binding moiety<br \/>\n<em>Mol Pharm<\/em>\u00a018(3) 966-975 (2021)<\/span><\/li>\n<\/ul>\n","protected":false},"excerpt":{"rendered":"<p>\u653e\u5c04\u6027\u30d7\u30ed\u30fc\u30d6\u306e\u4f53\u5185\u52d5\u614b\u306e\u5316\u5b66\u5236\u5fa1\u306b\u3088\u308b\u9ad8\u52b9\u7387\u30e9\u30b8\u30aa\u30bb\u30e9\u30ce\u30b9\u30c6\u30a3\u30af\u30b9\u7528\u30d7\u30e9\u30c3\u30c8\u30db\u30fc\u30e0\u306e\u69cb\u7bc9 RI\u3092\u57fa\u76e4\u3068\u3057\u3066\u8a3a\u65ad(Diagnostics)\u3068\u6cbb\u7642(Therapeutics)\u3092\u7cfb\u7d71\u7684\u306b\u7d71\u5408\u3059\u308b\u30e9\u30b8\u30aa\u30bb\u30e9\u30ce\u30b9\u30c6\u30a3\u30af\u30b9(Rad [&hellip;]<\/p>\n","protected":false},"author":14,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_acf_changed":false,"footnotes":""},"class_list":["post-2811","page","type-page","status-publish","hentry"],"acf":[],"_links":{"self":[{"href":"https:\/\/www.pharm.kyoto-u.ac.jp\/byotai\/wp-json\/wp\/v2\/pages\/2811","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.pharm.kyoto-u.ac.jp\/byotai\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/www.pharm.kyoto-u.ac.jp\/byotai\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/www.pharm.kyoto-u.ac.jp\/byotai\/wp-json\/wp\/v2\/users\/14"}],"replies":[{"embeddable":true,"href":"https:\/\/www.pharm.kyoto-u.ac.jp\/byotai\/wp-json\/wp\/v2\/comments?post=2811"}],"version-history":[{"count":5,"href":"https:\/\/www.pharm.kyoto-u.ac.jp\/byotai\/wp-json\/wp\/v2\/pages\/2811\/revisions"}],"predecessor-version":[{"id":3287,"href":"https:\/\/www.pharm.kyoto-u.ac.jp\/byotai\/wp-json\/wp\/v2\/pages\/2811\/revisions\/3287"}],"wp:attachment":[{"href":"https:\/\/www.pharm.kyoto-u.ac.jp\/byotai\/wp-json\/wp\/v2\/media?parent=2811"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}